Ignite Creation Date:
2024-05-06 @ 6:56 PM
Last Modification Date:
2024-10-26 @ 2:57 PM
Study NCT ID:
NCT05833906
Status:
COMPLETED
Last Update Posted:
2024-01-19
First Post:
2023-03-23
Brief Title:
Safety Tolerability and Pharmacokinetic Evaluations of CKR-051 After Transdermal Administration in Healthy Male Subjects
Sponsor:
CK Regeon Inc
Organization:
CK Regeon Inc
Study Overview
Official Title:
A Randomized Single-blind Placebo-controlled SingleMultiple Dose Dose Escalation Phase 1 Clinical Trial to Evaluate Safety Tolerability and Pharmacokinetic Characteristics of CKR-051 After Transdermal Administration in Healthy Male Subjects
Status:
COMPLETED
Status Verified Date:
2024-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will evaluate the safety tolerability and pharmacokinetics PK of CKR-051 in healthy participants
This study aiming to develop an agent for skin regeneration potential treatments include acute and chronic wounds cf Diabetic foot ulcers
This study aiming to develop an agent for skin regeneration potential treatments include acute and chronic wounds cf Diabetic foot ulcers
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None